The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota

LaCourse, Kaitlyn D; Zepeda-Rivera, Martha A.; Kempchinsky, Andrew G.; Baryiames, Alexander; Minot, Samuel S.; Johnston, Christopher A.; Bullman, Susan

doi:10.1016/j.celrep.2022.111625

Cited by 73 publications

(42 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, previous study found that Fusobacterium nucleatum was associated with colorectal cancer progression and poorer patient prognosis. 39 It was important to note that Megamonas was significantly enriched in GIR group when compared with PIR group, which indicated that the abundance of Megamonas may contribute to the recovery of CD4 + T cell.…”

Section: Discussionmentioning

confidence: 94%

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Zhao

Feng

Luo

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The association between gut microbiota and immunologic nonresponse among people living with HIV (PLHIV) on antiretroviral therapy (ART) is not well documented. This study aimed to characterize gut microbiota among HIV-infected men who have sex with men (MSM) with different immunologic responses. We recruited HIV-infected MSM and HIV-uninfected MSM (healthy controls, HC) in Guangzhou, June-October 2021. HIV-infected MSM were grouped into good immunological responders (GIR) (CD4 + T cell count ≥ 350 cells/μL) and poor immunological responders (PIR) (<350 cells/μL). Blood and stool samples were collected. Microbial translocation in serum was performed using enzyme-linked immunosorbent assay (ELISA). Bacterial 16S ribosomal DNA sequencing was performed on stool samples, and microbial metabolites were obtained through gas chromatography-mass spectrometry. 56 GIR, 41 PIR, and 51 HC were included. Microbial translocation marker soluble cluster of differentiation 14 (sCD14) in both GIR and PIR groups was significantly higher than that in HC. Compared with PIR or HC groups, the genera of Coprococcus, Blautia, Clostridium, and SMB53 were decreased, whereas Megamonas and Megasphaera were more abundant in GIR group. Compared with GIR or PIR groups, Bifidobacterium, Collinsella, Faecalibacterium, Oscillospira, and Roseburia were more abundant, whereas

show abstract

Section: Discussionmentioning

confidence: 94%

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Zhao

Feng

Luo

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The authors characterised the cancer mycobiome of 17,401 tissue and blood samples and found cancer-type specific mycobiomes. Noteworthy, gut microbiota do not only affect cancer progression but also impact responses to chemotherapy, radiation and immunotherapy, mainly due to a role in drug metabolism [110,111]. Recently, faecal microbiota transplantation was proposed as a promising therapeutic strategy to compensate for microbiota dysbiosis and to improve antitumour immune response [112].…”

Section: Microbiota's Contribution To Metastasismentioning

confidence: 99%

Circulating tumour cells in gastrointestinal cancers: food for thought?

et al. 2023

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers account for 35% of cancer-related deaths, predominantly due to their ability to spread and generate drug-tolerant metastases. Arising from different locations in the GI system, the majority of metastatic GI malignancies colonise the liver and the lungs. In this context, circulating tumour cells (CTCs) are playing a critical role in the formation of new metastases, and their presence in the blood of patients has been correlated with a poor outcome. In addition to their prognostic utility, prospective targeting of CTCs may represent a novel, yet ambitious strategy in the fight against metastasis. A better understanding of CTC biology, mechanistic underpinnings and weaknesses may facilitate the development of previously underappreciated anti-metastasis approaches. Here, along with related clinical studies, we outline a selection of the literature describing biological features of CTCs with an impact on their metastasis forming ability in different GI cancers.

show abstract

“…In addition to microorganisms within the digestive tract, the intratumoral microbiota has also drawn increasing attention in the era of precision medicine, since microbes colonizing the tumor microenvironment (TME) may be one of the causes leading to the cancer progression and the discrepancies in the efficacy of cancer therapies among patients. 21 – 26 Actually, the local diversity and neoplasm-associated significance of intratumoral microbes were not broadly and deeply investigated until the development of next- and third-generation sequencing in recent years, 27 – 29 despite their existence being reported a century ago. 30 In contrast to its intestinal counterpart, the complex characterization of the intratumoral microbiota is still at an infancy stage, and its roles have not been fully characterized, although some understanding has been gained regarding how it impacts tumorigenesis and therapeutic efficacy.…”

Section: Introduction and Overviewmentioning

confidence: 99%

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications

Zhao

Mei

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

In the past period, due to the rapid development of next-generation sequencing technology, accumulating evidence has clarified the complex role of the human microbiota in the development of cancer and the therapeutic response. More importantly, available evidence seems to indicate that modulating the composition of the gut microbiota to improve the efficacy of anti-cancer drugs may be feasible. However, intricate complexities exist, and a deep and comprehensive understanding of how the human microbiota interacts with cancer is critical to realize its full potential in cancer treatment. The purpose of this review is to summarize the initial clues on molecular mechanisms regarding the mutual effects between the gut microbiota and cancer development, and to highlight the relationship between gut microbes and the efficacy of immunotherapy, chemotherapy, radiation therapy and cancer surgery, which may provide insights into the formulation of individualized therapeutic strategies for cancer management. In addition, the current and emerging microbial interventions for cancer therapy as well as their clinical applications are summarized. Although many challenges remain for now, the great importance and full potential of the gut microbiota cannot be overstated for the development of individualized anti-cancer strategies, and it is necessary to explore a holistic approach that incorporates microbial modulation therapy in cancer.

show abstract

The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota

Cited by 73 publications

References 59 publications

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Circulating tumour cells in gastrointestinal cancers: food for thought?

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications

Contact Info

Product

Resources

About